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Abstract 
Background: Type 2 diabetes (T2D) is associated with reduced numbers and impaired function of circulating 
angiogenic cells (CAC) which contributes to the progression of atherosclerosis and microvascular disease. Previous 
studies suggest that short‑term infusion of unacylated ghrelin (UAG) normalizes CAC number in patients with T2D. 
To determine dose‑dependent effects of short‑term infusion of UAG in T2D patients using a cross‑over model, and of 
long‑term infusion of UAG in obese mice, on differentiation of monocyte progenitors into CAC.
Methods: Eight overweight T2D patients were infused overnight with 3 and 10 µg/kg/h of UAG in a double‑blind, 
placebo‑controlled cross‑over study. To assess the effects of long‑term UAG treatment, obese mice were infused with 
UAG for 4 weeks. Monocyte progenitors were assessed for their ability to differentiate into CAC in vitro.
Results: In T2D patients, UAG treatment caused a reduction in differentiation of CAC, dependent on UAG dose and 
differentiation method. However, mice treated with UAG showed a significant increase in differentiation of bone mar‑
row progenitors into CAC.
Conclusion: UAG causes a minor suppressive effect on CAC development after short‑term treatment in humans, but 
experiments in mice suggest that long‑term treatment has beneficial effects on CAC formation.
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Background
Ghrelin is a 28 amino acid peptide that is secreted pre-
dominantly by X/A-like cells in the stomach. It circu-
lates in two different forms: acylated ghrelin (AG) and 
unacylated ghrelin (UAG; also named des-acyl ghrelin) 
[1, 2]. AG is acylated with octanoic acid at serine 3 by 
ghrelin O-acyl transferase (GOAT), whereas UAG is not 
[3]. Ghrelin was discovered in 1999 as the endogenous 
ligand of the orphan growth hormone secretagogue 
receptor (GHSR1a) that had previously been identified 
as the receptor mediating the pharmacological effects of 
a new therapeutic class of compounds, the growth hor-
mone secretagogues [4]. Ghrelin was initially character-
ized for its property of inducing growth hormone (GH) 
secretion, a function mediated by GHSR1a [4].
Today, however the ghrelin system is known to exert 
numerous biological effects on the secretion of several 
pituitary hormones, on gastric acid secretion and gut-
motility, on exocrine and endocrine pancreatic function 
and glucose metabolism, appetite stimulation and the 
cardio-vascular and immune system [2, 5]. Since UAG 
only activates GHSR1a at supra-physiological concentra-
tions [6], and has no physiological effect on GH secretion 
[7], it has long been considered not to have a physiologi-
cal role.
Clinical evidence suggests that UAG prevents the dia-
betogenic effects of AG in healthy volunteers and in 
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GH-deficient patients [2, 8], primarily by improving 
insulin-sensitivity. Importantly, we have recently shown 
that UAG treatment rapidly improves insulin sensitivity 
in type 2 diabetic subjects [9]. How it can exert effects in 
several disparate (patho)physiological systems and con-
ditions remains to be answered. In metabolically active 
tissues of GHSR-deficient mice, UAG rapidly modulates 
lipogenic and insulin signaling pathway gene expres-
sion [10], indicating a GHSR-independent mechanism of 
action, although a receptor for UAG remains to be dis-
covered. Recently, we have also shown that UAG infusion 
in obese mice causes insulin-sensitizing effects [11].
Vascular complications are the major source of mor-
bidity and mortality among patients with diabetes [12]. 
Diabetes mellitus is associated with a 2- to 4-fold increase 
in rates of macrovascular disease [13]. This is due to 
macrophage accumulation in the vascular wall and sub-
sequent secretion of multiple proinflammatory growth 
factors and cytokines, a very important step in the patho-
logical mechanism causing atherosclerosis [14].
Monocytes and monocyte-derived cells are important 
in detecting and repairing vascular damage, in particu-
lar by producing proangiogenic factors which promote 
neovascularization and endothelial repair. These vessel-
protective cells have previously been indicated as myeloid 
EPC [15, 16], but are now more accurately termed pro-
angiogenic cells or circulating angiogenic cells (CAC). 
We will use the latter term throughout this study. CAC 
are involved in restoration of vascular homeostasis in dia-
betics. Monocyte differentiation and function in patients 
with diabetes is altered by metabolic conditions, resulting 
in the decreased ability of these cells to participate in vas-
cular maintenance and repair [17–19]. Data from recent 
experiments on CAC suggest that UAG may beneficially 
impact the vascular remodeling process which is known 
to be impaired in type 2 diabetes patients [20, 21].
The aims of the current study are to extend the find-
ings of Togliatto et al. by examining the dose and time-
dependent effects of in  vivo UAG treatment on in  vitro 
differentiation of isolated monocytes into CAC using dif-
ferent protocols, and into their presumed non-protective 
counterparts, macrophages. To do this, we first examined 
the effects of a short-term, i.e. overnight infusion of UAG 
at 3 and 10 µg/kg/h in T2D patients on differentiation of 
peripheral blood monocytes into CAC and macrophages. 
Since long-term UAG treatment of humans is not ethi-
cally feasible, we infused lean and obese mice with vehi-
cle or UAG at 10  µg/kg/h for 4  weeks and examined 
their effect on differentiation of CAC from bone marrow 
monocyte progenitors.
Methods
Study drug
UAG was obtained from Bachem AG, Hauptstrasse 144, 
Bubendorf CH-4416, Switzerland. UAG was delivered as 
lyophilized powder (vials containing 5  mg of drug) and 
stored as indicated by the manufacturer. The same pep-
tide preparation was used for both animal and human 
experiments.
Human peripheral blood mononuclear cell cultures
Study design
This study is a single-center, investigator-initiated, dou-
ble blind and placebo-controlled randomized study [9]. 
The study was conducted in Erasmus University Medi-
cal Center Rotterdam after approval by the local IRB. 
All subjects gave their written informed consent before 
enrollment. The study included three overnight hospital 
admissions. During these three admissions, all subjects 
received either placebo, or UAG at 3 or 10 μg/kg/h in ran-
domized order as a continuous infusion via an indwelling 
catheter as described below. A washout period of at least 
1 week was used between the different treatment periods.
Placebo or UAG was continuously infused for 15  h 
from 22:00  h until 13:00  h the next day. At 8:00–8:15  h 
the following morning, a standard breakfast meal (SBM) 
was served: 714 kcal (46% fat, 17% proteins, 37% carbo-
hydrates). Before the start of each infusion period a con-
tinuous glucose monitor (iPro2, Medtronic trading, The 
Netherlands) was inserted to measure the subcutaneous 
interstitial blood glucose [22–25].
Blood samples for isolating monocyte progenitors were 
collected before (16:00) and after (the next day at 14:00) 
the infusion period.
Subjects
Eight subjects were enrolled (2 females–6 males; mean 
age 53 years (range 31–65 years). Mean body mass index 
(BMI) was 31.5 kg/m2, range 26–40.1 kg/m2. All subjects 
were diagnosed with type 2 diabetes for at least 3 months 
prior to enrollment. Mean glycosylated hemoglobin lev-
els (HbA1c) were 49 (41–55) mmol/mol [6.6 (5.9–7.2)%]. 
Exclusion criteria were a history or presence of long-
term type 2 diabetes complications; clinically significant 
abnormalities in laboratory evaluation at screening, and 
the use of systemic corticosteroids within 60  days prior 
to screening.
Four of eight patients were medicated with statins and 
two with antihypertensive drugs. All patients were being 
treated with metformin that was stopped 1 day prior to 
the start of each treatment period.
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Peripheral blood mononuclear cell cultures
Peripheral blood mononuclear cells (PBMC) were 
obtained by density gradient centrifugation (Ficoll-Paque 
PLUS, GE Healthcare 17-1440-03) of 50  ml of periph-
eral blood collected in sodium heparin tubes. CAC, also 
called early endothelial progenitor cells (EPC) or myeloid 
EPC, were cultured according to two different protocols 
as described by Murohara et  al. and by Asahara et  al. 
[26, 27]. These cultures are referred to as Toyo-CAC and 
EBM-CAC, respectively.
In both cultures, PBMC were plated in triplicate 
at a density of 2  ×  106  cells/ml/well in 24-well plates 
(Nunc) coated with 10  μg/ml of human fibronectin 
(Sigma). For Toyo-CAC, cells were cultured in M199 
medium supplemented with 10% FCS, 0.05  mg/ml 
bovine pituitary extract (Invitrogen), 10,000  U  penicil-
lin/ml, 10,000  U  streptomycin/ml (Lonza DE17-602E), 
and 10  units/ml heparin (Leo Pharma BV) at 37  °C 
and 5%  CO2. For EBM-CAC, cells were cultured in 
EBM-2  +  EGM-2 (Lonza 3156; 4176) at 37  °C and 5% 
 CO2. After 7 days of culture, Toyo-CAC and EBM-CAC 
cultures were washed profusely with PBS to retain only 
the adherent spindle-shaped cells. Cells were then fixed 
with paraformaldehyde (PFA, 4%) for 15  m at room 
temperature.
To generate human macrophages from monocytes under 
similar conditions, total PBMC were cultured in triplicate 
at a density of 1 x 106 cells/well at 37  °C and 5%  CO2 in 
24-well plates for 7  days in RPMI (25  mM Hepes, with 
Ultraglutamin-1) supplemented with human AB serum 
(Lonza 14-490E), 10,000 U penicillin/ml, 10,000 U strepto-
mycin/ml (Lonza DE17-602E), and 10% M-CSF-contain-
ing conditioned medium from Ladmac cells [28]. Fresh 
growth factor (100  μl) was added to each well on days 3 
and 6. At day 7, plates were centrifuged at 1200  rpm for 
3 min at 4 °C and cells were fixed with PFA (4%).
The quantification of cultures was performed fluoro-
metrically on the basis of DNA content as assessed by 
propidum iodide staining [29]. Briefly, wells were incu-
bated with 20 μl propidium iodide (4 μl/ml; Sigma). After 
10 min the fluorescence intensity was measured using a 
FLUOstar Optima plate reader (BMG Labtech, Orten-
berg, Germany). Interpolation on a standard curve of 
PBMC was used to determine absolute cell numbers.
Differentiation of CAC from bone marrow of lean 
and obese mice infused with UAG
C57BL/6 mice (10  week, male; Charles River Labora-
tories, Maastricht, The Netherlands) were maintained 
at 12:12  h light: dark, 21  °C, with free access to food 
and water. Normal (ND) and high fat (HFD) diets were 
from special diets services (Tecnilab-BMI, Someren, The 
Netherlands; product code 801722, 9%  kcal from fat, 
69% from carbohydrate, 22% from protein) and ABDiets 
(Woerden, The Netherlands; 41% kcal from fat, 40% kcal 
from carbohydrate, 19% kcal from protein), respectively. 
Animal experiments were performed with the approval 
of the Animal Ethics Committee at Erasmus MC 
(approval code: EMC2050). Mice were implanted with 
subcutaneous Alzet 1004 mini-osmotic pumps (Durect 
Corp., Cupertino, CA, USA) containing saline or UAG. 
UAG was infused at 10  µg/kg/h. Mice were split into 
two groups 2 weeks after pump implantation (n = 3 for 
each of the 4 experimental groups), either continuing to 
receive the ND or given free access to the HFD, as previ-
ously described [11]. At the end of the 4  week infusion 
period, bone marrow was collected from the femurs and 
tibiae, and culture of CAC/endothelial progenitor cells 
was performed as previously described [30].
Weight and food intake were recorded 1  week before 
and weekly during the period of treatment. Data on 
weight, fat mass, glucose and insulin levels in these mice 
are described in Delhanty et al. [11].
Results
Assessment of dose‑dependent effects of UAG in humans
Baseline values of generated EBM-CAC, Toyo-CAC 
and macrophages are shown in Fig.  1, representing 
the retrieval of these cell types from cultures of PBMC 
obtained before the initiation of treatment. In both 
types of CAC cultures as well as in the macrophage cul-
tures, a significant degree of variation was observed with 
respect to the absolute number of CAC and macrophages 
retrieved. This variation occurred not only between dif-
ferent patients, but also among different samples from 
the same patients obtained at different visits. Baseline 
culture results from some patients were relatively con-
sistent, while results from others showed high degrees 
of variation, suggesting a strong influence of variable 
patient conditions upon admission. Furthermore, cells 
from some patients showed a virtually complete inabil-
ity to generate either type of CAC and/or macrophages. 
For instance, cells from patient #7 generated virtually no 
EBM-CAC and macrophages, while Toyo-CAC could be 
readily measured. Another patient #2 generated virtually 
no Toyo-CAC or macrophages, but EBM-CAC could be 
shown, though at variable levels. These baseline findings 
also indicate that both types of CAC cultures and mac-
rophage cultures measure essentially distinct param-
eters. This is confirmed by a correlation analysis of the 
culture yields before and after treatment (Figs. 2, 3). This 
shows that a significant correlation exists only between 
the quantity of EBM-CAC and macrophages at baseline 
(Fig. 2b), but this correlation is lost after treatment with 
UAG (Fig. 3b).
Page 4 of 9Özcan et al. Diabetol Metab Syndr  (2017) 9:43 
The effect of treatment of patients with 3 or 
10  µg  UAG/kg/h on CAC and macrophage numbers is 
shown graphically for each patient in Fig. 4. Table 1 indi-
cates the quantification of these changes, expressed as 
mean cell count normalized to the mean pre-treatment 
value. Clearly, the treatment effects were very diverse, 
and major differences between and among patients 
were observed. Even the direction of change differed, 
although for both types of CAC cultures high pre-treat-
ment measurements tended to decrease upon treatment, 
EBM-CAC TOYO-CAC macrophages
a b c
#1 #2 #3 #4 #5 #6 #7 #8
0
1.0×105
2.0×105
3.0×105
4.0×105
Patient
# 
EB
M
-C
A
C
 / 
w
el
l
#1 #2 #3 #4 #5 #6 #7 #8
0
2.0×105
4.0×105
6.0×105
8.0×105
1.0×106
1.5×1006
2.0×1006
2.5×1006
Patient
# 
To
yo
-C
A
C
 / 
w
el
l
#1 #2 #3 #4 #5 #6 #7 #8
0
1.0×106
2.0×106
3.0×106
Patient
# 
M
ac
ro
ph
ag
es
 / 
w
el
l
Fig. 1 Baseline values for the generation of Toyo‑CAC, EBM‑CAC, and macrophages. PBMC were isolated from patients at admission, before 
treatment, and cultured under different conditions to generate EBM‑CAC (a), Toyo‑CAC (b), or macrophages (c). Each of the three data‑points per 
patient represents the average of three replicate wells
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Fig. 2 Correlation between EBM‑CAC, Toyo‑CAC and macrophage baseline culture yields. Outcomes of EBM‑CAC, Toyo‑CAC and macrophage cul‑
tures were correlated. A significant correlation was observed only between EBM‑CAC and macrophage cultures (b), but not between the two types 
of CAC cultures (a), or the Toyo‑CAC and macrophages (c)
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Fig. 3 Correlation between EBM‑CAC, Toyo‑CAC and macrophage culture yields after UAG treatment. Outcomes of EBM‑CAC, Toyo‑CAC and mac‑
rophage cultures from PBMC obtained after treatment with UAG were correlated. No significant correlation was observed between the two types of 
CAC cultures (a), between EBM‑CAC and macrophage cultures (b), or the Toyo‑CAC and macrophages (c)
Page 5 of 9Özcan et al. Diabetol Metab Syndr  (2017) 9:43 
while low pre-treatment values increased (Fig.  4a, b). 
Only in two conditions were statistically significant dif-
ferences observed between pre- and post-treatment 
samples: treatment with 10 µg/kg/h UAG reduced EBM-
CAC to 70% (p = 0.045), while treatment with 3 µg/kg/h 
UAG caused reduction of Toyo-CAC to 60% (p = 0.038) 
(Table 1). Enigmatically, however, in both cases treatment 
with the lower or higher concentration, respectively, did 
not show a similar trend.
For the macrophage cultures, the yield of cells post-
treatment tended to decrease in all cases including pla-
cebo treatment (Fig.  4c), although single measurements 
showing increased macrophage yield prevented attain-
ment of statistical significance.
Assessment of long‑term treatment with UAG in mice
Since short-term treatment of humans with UAG had 
relatively inconsistent effects, we wanted to determine 
if longer-term treatment might change this outcome. 
However, for ethical reasons, long-term treatment of 
humans is not yet possible. Therefore we used a model of 
diet-induced obesity in mice. The HFD caused a signifi-
cant increase in fat mass which was prevented by infu-
sion of UAG, as described in our previous publication 
[11]. In that study, we also found that UAG infusion pre-
vented the glucose intolerance and insulin resistance that 
accompanied this increase in fat mass. Testing the effect 
of 4 weeks of UAG infusion on the differentiation of CAC 
from bone marrow progenitors showed that infusion of 
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Fig. 4 Treatment‑related changes in the quantity of obtained EBM‑CAC, Toyo‑CAC and macrophages. For each patient, the yields of EBM‑CAC (a), 
Toyo‑CAC (b) and macrophages (c) derived from PBMC isolated from pre‑ and post‑treatment samples are shown. Each data point represents the 
average of three individual wells. Quantitative analysis of these data is shown in Table 1
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UAG in both ND-fed lean mice as well as mice given a 
short-term HFD caused a consistent, significant increase 
in recovery of CAC from bone marrow cultures (Fig. 5).
Discussion
Previous studies have indicated that T2D is associ-
ated with reduced numbers of monocyte-derived CAC 
[17–19]. Reduced numbers and impaired function of 
these monocytes in diabetes increased atherosclerosis. 
Endothelial injury is thought to represent an impor-
tant step in the initiation and progression of atheroscle-
rotic vascular disease [31]. As mentioned earlier, UAG 
may have beneficial effects on the vascular remodeling 
process in T2D patients [20, 21]. Early CAC play a very 
important role in this process. To further investigate 
the effect of UAG treatment on CAC, and compare 
this to macrophage-forming potential, we performed 
two in  vivo studies: a short-term study to assess dose-
dependency of UAG effects in T2D patients; and a study 
to investigate the effects of long-term UAG treatment in 
mice with decreased insulin sensitivity induced by diet-
induced obesity. In humans, we studied the effects of a 
continuous overnight infusion of UAG or placebo in 
eight overweight mild type 2 diabetics. We found that 
short-term infusion of UAG had significant suppressive 
effects on CAC number at different doses, but this was 
dependent on differentiation procedure. Our findings are 
not consistent with those of Togliatto who found that sys-
temic overnight administration of UAG at 3 µg/kg/h (our 
low dose) prevented diabetes-induced EPC decrease, 
and increased endothelial progenitor cell mobilization in 
individuals with T2D [20]. It is currently unknown how 
UAG interferes with the differentiation of the cells. There 
is evidence for an Akt-eNOS-MMP9-sKitL pathway that 
could be involved in release of EPCs into the circulation 
[20]. The most important explanation for these conflict-
ing results is the heterogeneity in our population. The 
variation, shown in Fig. 4c, within and among patients is 
too large to draw firm conclusions; in general, there is no 
clear effect of the treatment, other than a slight decrease 
rather than the expected increase of CAC numbers fol-
lowing UAG treatment. An important difference between 
the studies was that the T2D subjects described in the 
paper of Togliatto et  al. had not been medicated [20]. 
They were treated with diet alone. In contrast, four of our 
eight patients were on statins and two used antihyperten-
sive medication. Davignon et al. [32] showed that statins 
generate potent anti-inflammatory actions and can also 
improve dysfunctional EPC populations in vitro [33–36]. 
A potential molecular mechanism of statin action on EPC 
might involve the PI3 K/Akt pathway [34] and the inhi-
bition of apoptosis [37]. In our population four patients 
received statin treatment (patient 1, 4, 5 and 8). The sta-
tin treatment was put on hold 1 day before testing. With 
their long half- life, especially of atorvastatin, we can still 
expect a carry-over effect during the UAG administra-
tion in our study. However, a sub-analysis of the statin-
using group showed no significant differences between 
this group and the subjects that did not use statins. This 
may be caused by the large inter- and intra-individual 
differences and the small group size. Other studies show 
that the angiotensin-converting enzyme (ACE) inhibi-
tors such as ramipril [38] and angiotensin II (AT II) 
inhibitors, like valsartan [39] can increase EPC levels in 
Table 1 Treatment-related changes in  the yield of  CAC 
and macrophages
For each patient, the baseline values of that specific visit were compared with 
culture yields after treatment
a The mean obtained cell number of pre-tx samples was set at 1; mean post-tx 
number is expressed relative to this ± SD
b Significance was determined by paired t test
Culture Treatment Normalized mean cell 
count post‑txa
p  valueb
EBM‑CAC Placebo 1.1 ± 1.2 0.219
3 µg/kg/h 1.0 ± 1.0 0.938
10 µg/kg/h 0.7 ± 0.6 0.045
Toyo‑CAC Placebo 0.8 ± 0.7 0.507
3 µg/kg/h 0.6 ± 0.4 0.038
10 µg/kg/h 1.2 ± 0.8 0.780
macrophages Placebo 0.6 ± 0.5 0.053
3 µg/kg/h 0.9 ± 0.4 0.617
10 µg/kg/h 1.0 ± 0.8 0.097
Fig. 5 Effect of UAG infusion endothelial progenitor cell recovery 
from murine bone marrow cell cultures. Mice infused for 4 weeks 
with UAG fed either a normal or high fat diet during the last 2 weeks 
of treatment. Bone marrow was then isolated and cultured to gener‑
ate endothelial progenitor cells (aka. CAC). The data represents the 
average recovery of cells in three replicate wells of bone marrow 
cells from three different mice. (*p < 0.05; **p < 0.01 versus ND saline 
group; ANOVA)
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patients, probably interfering with the CD26/dipepti-
dyl peptidase IV system. One patient used ramipril, but 
this treatment was not associated with an increase in the 
number of circulating CAC. Furthermore, all patients 
were being treated with metformin, that was stopped 
1 day prior to the start of each treatment period. Chronic 
treatment with metformin in obese patients with T2D 
did not change ghrelin levels before and after start with 
metformin [40]. Ida et al., showed in 12 RCTs that there 
were no significant differences in ghrelin levels [41]. The 
effect of metformin on UAG is unknown. If there is an 
effect on UAG, it was similarly in all the patients because 
metformin was stopped at the same time in all patients. 
Another explanation for our inconclusive results is 
the notion that our population with a mean HbA1c of 
49 mmol/mol (6.6%) was well regulated. Loomans et  al. 
[30] observed a significant inverse correlation between 
the number of circulating EPC and HbA1c levels in 
patients with type 1 diabetes. On average, this popula-
tion had a 40% reduction in the circulating number of 
short term cultured EPC, and an HbA1c of more than 8% 
[30]. These EPC were cultured as described by Murohara 
[26], described in our study as Toyo-CAC. The question 
remains whether the number of CAC are affected in our 
mild diabetics. Loomans et  al. obtained similar results 
in a hyperglycemic mouse model [30]. In this study, it 
was found that HMG-CoA (3-hydroxy-3-methylglutaryl 
coenzyme A) reductase inhibitors overcome the effects of 
hyperglycemia on EPC. Adding this Atorvastatin in vitro 
to bone marrow differentiation cultures increased the 
number of EPC and conversely decreased the number of 
macrophages. Interestingly, this study showed that sta-
tin treatment directly increases myeloid EPC generation 
in vitro from BM precursors derived from mice rendered 
diabetic by streptozotocin treatment.
In all human samples placebo treatment decreased 
the yields in macrophage cultures. Maybe this is due to 
the change of environment. For example the stress of a 
hospital visit may have caused lower numbers of mac-
rophages. Pre-treatment samples were taken within 1  h 
after admission and it is known that stress and physi-
cal activity increase numbers of circulating leukocytes, 
including monocytes [27, 42]. Furthermore, the numbers 
of circulating cells, including monocytes and different 
populations of EPC, are known to be influenced by cir-
cadian variation [43, 44]. Since pre- and post-treatment 
collection of peripheral blood differ only by 3 h (i.e. 16:00 
vs. 13:00 h), it is unlikely that this difference plays a sig-
nificant role in the observed variability.
An explanation for the high degree of variation 
observed in the CAC and macrophage cultures can only 
be speculative at this point. Technical variation may 
add to the diversity, although we have reason to believe 
that this contribution is limited. As indicated above, we 
obtained a very consistent yield of CAC and/or mac-
rophages in a number of pre-treatment samples from 
individual patients, and these values were acquired in 
cultures generated over several weeks and at different 
time points during the study. That leaves a potentially 
significant contribution of inter- and intra-individual 
differences induced by inborn as well as environmental 
conditions as the most likely reason for the observed var-
iability in CAC and macrophage generation.
We have previously reported that a short-term high 
fat diet causes a doubling in abdominal white fat mass 
in mice, and significantly impairs insulin sensitivity and 
glucose tolerance [11]. Using this model we showed 
that long-term (4  week) UAG infusion at 10  µg/kg/h 
blocked these effects. Utilizing mice from this study 
we here also assess the ability of bone marrow progeni-
tors to differentiate into CAC in either vehicle or UAG 
infused lean or obese mice. Like Togliatto et  al. we 
found that UAG caused an increase in recovery of CAC 
from differentiated bone marrow cell cultures in obese 
mice [20]. However, we also find a similar effect in lean 
mice. In either diet condition, we observed no changes 
in the generation of macrophages from bone marrow 
precursors upon treatment with UAG, as reported in 
our previous study [11]. These data might suggest that 
longer term treatment in humans may be necessary to 
observe consistent effects of UAG treatment on CAC, 
however additional studies are necessary, to confirm 
this.
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